Renalytix Plc (AIM:RENX)
1.860
-0.040 (-2.11%)
Jun 17, 2026, 3:34 PM GMT
Renalytix Revenue
Renalytix had revenue of $800.00K USD in the quarter ending December 31, 2025, with 36.52% growth. This brings the company's revenue in the last twelve months to $3.30M, up 40.31% year-over-year. In the fiscal year ending June 30, 2025, Renalytix had annual revenue of $3.00M with 30.43% growth.
Revenue (ttm)
$3.30M
Revenue Growth
+40.31%
P/S Ratio
3.39
Revenue / Employee
$71.74K
Employees
46
Market Cap
8.30M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.00M | 700.00K | 30.43% |
| Jun 30, 2024 | 2.30M | -1.10M | -32.41% |
| Jun 30, 2023 | 3.40M | 433.00K | 14.58% |
| Jun 30, 2022 | 2.97M | 1.48M | 99.20% |
| Jun 30, 2021 | 1.49M | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 45.77B |
| GSK plc | 32.78B |
| Haleon | 11.03B |
| Smith & Nephew | 4.58B |
| RUA Life Sciences | 4.46M |
| GENinCode | 3.08M |
| Verici Dx | 1.40M |
| OptiBiotix Health | 1.17M |
Renalytix News
- 5 weeks ago - Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention - PRNewsWire
- 2 months ago - Renalytix Quarterly report: H1 2026 - Filings
- 4 months ago - Renalytix Earnings release: H1 2026 - Filings
- 7 months ago - Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes - PRNewsWire
- 8 months ago - Renalytix Annual report: Q4 2025 - Filings
- 9 months ago - Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease - PRNewsWire
- 11 months ago - MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities - PRNewsWire
- 1 year ago - Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025 - PRNewsWire